Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Publication Type:

Journal Article


The New England journal of medicine, Volume 358, Issue 25, p.2698-703 (2008)


2008, Antibodies, Neoplasm, Antigens, Neoplasm, CD4-Positive T-Lymphocytes, Center-Authored Paper, Clinical Research Division, Cytokine Analysis Core Facility, Experimental Histopathology Core Facility, Flow Cytometry Core Facility, Humans, Immune Monitoring Core Facility, Immunoglobulin G, IMMUNOTHERAPY, Male, MELANOMA, Membrane Proteins, Middle Aged, Remission Induction, Shared Resources


We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.